Dataset opportunity
Atriva Therapeutics — 医疗影像数据集机会
Atriva Therapeutics 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
70.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
2025 年全球医疗影像人工智能市场价值为 18.8 亿美元，预计复合年增长率为 36.91%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Atriva Therapeutics 持有其专有候选药物（如 Zapnometinib）临床试验的专业医疗影像数据集。该数据集整合了影像模态与相应的医疗记录、物联网数据和监管证据，提供了一个全面的多模态资源，非常适合开发和验证高精度诊断人工智能算法。
2025 年全球医疗影像人工智能市场价值为18.8 亿美元，预计将以惊人的36.91% 的复合年增长率扩张。[2] 虽然由于敏感的患者健康信息 (PHI) 和专有知识产权，访问权限复杂，但该试验数据的稀有性和临床丰富性使其具有极高的价值，为旨在抢占这一快速增长市场份额的买家提供了独特的优势。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床试验数据涉及高度敏感的患者健康信息 (PHI)，受严格的 GDPR 和 EMA 法规约束；数据与专有候选药物（Zapnometinib）相关联，知识产权保护是任何共享的主要考虑因素；访问需要浏览可能孤立的临床研究报告 (CSR) 和患者级别原始数据。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Atriva Therapeutics 持有其抗病毒治疗II 期临床试验的专有、多模态数据集。患者反应数据、临床前研究和分子水平生物标志物信息的这种独特组合是医疗人工智能和诊断影像公司的稀有资产。它直接满足了培训复杂的诊断人工智能以预测治疗效果的迫切需求，这是医疗影像人工智能市场的关键驱动因素，预计该市场将以超过 36% 的复合年增长率增长。该数据集提供了构建下一代病毒感染预测模型所需的真实情况。
See dimension details ↓- Dataset Specificity90
主导的‘医疗记录’，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家对高质量、临床基础影像数据的需求非常强劲，这得益于医疗影像人工智能市场的快速增长，该市场正以 36.91% 的复合年增长率扩张。[2]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Atriva Therapeutics 是一家临床阶段的生物制药中小型企业，其核心业务是开发抗病毒药物；在此过程中产生的临床试验数据，包括医疗影像，是有价值的、未经商业化的副产品，使其成为理想的目标。问题：该公司处于临床阶段，一个数据源表明其“已停业”并已进行清算，这对其运营构成了重大风险；数据（临床试验结果、患者影像）高度敏感，并受严格的医疗隐私法规（例如 GDPR、HIPAA）的约束，这可能会带来复杂性；其一项关键临床试验（NCT04776044）因招募问题而提前终止，这可能会影响相关数据集的完整性。[8]
- Deep Qualification90
✓ 通过 — 目标是一家生物制药公司，拥有其药物开发项目产生的有价值的临床试验数据，这是其核心业务的副产品。这些数据，包括患者记录和可能用于呼吸系统疾病的医疗影像，高度敏感（PHI），其使用受到严格监管，直接商业化复杂且受到重大法律和知识产权限制。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该数据集包含 II 期 RESPIRE 研究的专有临床试验数据，详细说明了患者对新型抗病毒药物的生理反应，这对于在真实治疗结果上培训和验证诊断人工智能模型至关重要。
Regulatory records
它包括关于该药物针对流感和冠状病毒作用机制的广泛临床前数据，提供了构建更强大和可解释人工智能系统所需的根本生物学背景。
IoT / sensor data
该集合具有高分辨率的生物标志物和细胞信号数据，提供了治疗效果的时间序列视图，这对于开发用于患者分层和反应的预测模型非常有价值。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Atriva Therapeutics Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.88 billion in 2025, projected to grow at a CAGR of 36.91% (source: Fortune Business Insights). [2]. Investment score 70.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Gurusystems — 传感器遥测数据集机会
View opportunity →工业Nyobolt — 工业运营数据集商机
View opportunity →工业Customcells — 工业运营数据集机会
View opportunity →